R. P. Edwards

Targeted treatment of recurrent platinum-resistant ovarian cancer : current and emerging therapies

A. Vlad, G. Mantia-Smaldone, R. P. Edwards, 2010 .

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion.

J. Kirkwood, R. Hammond, B. Lembersky, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells

F. Monzon, S. Khan, R. Edwards, 2008, Oncogene.

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

R. Edwards, N. Finkler, D. Irwin, 2004, International Journal of Gynecologic Cancer.

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

C. Tannenbaum, P. Rayman, P. Pavicic, 2023, Oncoimmunology.

Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies

Y. Bang, S. Ramalingam, S. Strychor, 2012, Journal of clinical pharmacology.

Pharmacokinetic Study of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies

S. Ramalingam, S. Strychor, S. Ramalingam, 2009, Clinical pharmacology and therapeutics.

IL‐12 receptor‐mediated upregulation of FasL in human ovarian carcinoma cells

J. Grandis, A. Lokshin, E. Gorelik, 2004, International journal of cancer.